Listen to this article Mark T. Esser, vice president for vaccines and immune therapies at pharmaceutical giant AstraZeneca, will be the inaugural chief scientific officer and leader of the Paul and ...

Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.

AstraZeneca’s experimental pill has shown promise in reducing “bad” cholesterol, raising expectations for more convenient ...

AstraZeneca Pharmaceuticals LP and a Christian sales specialist have agreed to settle his suit over the company’s failure to ...

AstraZeneca has been busy in recent years pumping up its oncology pipeline via a shopping list of assets and companies. | ...

Shares in many large drugmakers initially fell Wednesday on the president's threat, only to rebound later when he announced a ...

Investors are nervous. As of 9:55 a.m. ET Wednesday morning, shares of Roche Holding ( RHHBY -2.81%) are down 2.3%, Eli Lilly ( LLY -4.38%) stock is off 3.2%, and AstraZeneca ( AZN -4.87%) is doing ...

Goldman Sachs analyst Rajan Sharma maintained a Buy rating on AstraZeneca (AZN – Research Report) today and set a price target of £153.18. The ...

In a report released today, Justin Smith from Bernstein maintained a Buy rating on AstraZeneca (AZN – Research Report), with a price target of ...

In the latest market close, Astrazeneca (AZN) reached $64.90, with a -1.35% movement compared to the previous day. The stock's change was more than the S&P 500's daily loss of 1.57%. Elsewhere, the ...

Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch ...

As the countdown to the launch of its first therapeutic continues, Rocket Pharmaceuticals is fueling up its commercial team.